Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Cellular Biomedicine Group Inc. Stories

2013-12-13 16:24:24

PALO ALTO, Calif., Dec. 13, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. The...

2013-11-09 08:20:28

PALO ALTO, Calif., Nov. 9, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today convened the annual meeting of its shareholders. Because a quorum was not achieved by shares present at the meeting in person or by proxy, the shareholder meeting was adjourned to a later date as to be determined by the board of directors of the Company. The board of directors has fixed the close of business on November 18, 2013 as the record date for the determination of stockholders...

2013-11-07 16:30:24

PALO ALTO, Calif., Nov. 7, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today reminded all its shareholders that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each...

2013-11-05 12:28:46

PALO ALTO, Calif., Nov. 5, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin(TM),( )a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of...

2013-11-01 12:27:22

PALO ALTO, Calif., Nov. 1, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin(TM),( )a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. The...

2013-10-30 08:32:37

A-Stromal(TM) - The first certified product of its kind for adipose stromal cell purification in China PALO ALTO, Calif., Oct. 30, 2013 /PRNewswire/ -- Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal(TM) adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These...

2013-10-25 12:24:03

PALO ALTO, Calif., Oct. 25, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder...

2013-10-14 12:23:59

PALO ALTO, Calif., Oct. 14, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced that the Board of the Company has appointed three new independent directors to the Board, namely, Leo Dembinski, David Bolocan and Jeff Auerbach. Mr. Dembinski is a Certified Public Accountant with 30 years of experience as a controller and a senior financial and operating executive for a major retailer in Chicago. As CEO of CPS Direct Marketing, in Phoenix Arizona, he...

2013-10-01 08:31:02

PALO ALTO, Calif., Oct. 1, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) announced today that it has promoted Dr. Wei (William) Cao to serve as its Chief Executive Officer. Dr. Cao will replace Dr. Wen Tao (Steve) Liu, the Chairman and CEO, who will step down as CEO to focus on CBMG's North America strategy and to provide leadership for the company's board of directors. Dr. Cao previously served as the company's President and a director on the board. Dr. Cao...

2013-09-11 12:24:01

PALO ALTO, Calif., Sept. 11, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO") as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC"). The Board of Directors of Cellular Biomedicine Group, Inc. determined that this change of auditor was in...